Trial Profile
Randomised Open Label Adaptive Phase III trial of addition of Belinostat to chemotherapy in patients with locally advanced potentially resectable Thymic Epithelial Tumors (TET)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Nov 2023
Price :
$35
*
At a glance
- Drugs Belinostat (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 05 Feb 2018 New trial record